CRDF EBITDA | CARDIFF ONCOLOGY, INC.

CARDIFF ONCOLOGY, INC. (CRDF) EBITDA

2026-06-30: Basis Reported; EBITDA -$9.53M*; Operating income -$9.62M; Depreciation and amortization $87.00K*.
2026-03-31: Basis Reported; EBITDA -$12.76M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$7.74M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$11.88M*; Operating income -$11.97M; Depreciation and amortization $89.00K*.

Complete source-backed ebitda history.

Available history: 2011-03-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$9.53M*	-$9.62M	$87.00K*	$104.00K	-9161.54%*	(m)	-$11.77M*	(m)	(m)	$3.80M	(m)
2026-03-31	Reported	-$12.76M	(m)	(m)	(m)	-31129.27%	(m)	-$12.29M	(m)	(m)	$6.13M	(m)
2025-12-31	Reported	-$7.74M	(m)	(m)	(m)	-3184.77%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$11.88M*	-$11.97M	$89.00K*	$120.00K	-9904.17%*	$18.00K*	-$10.83M*	(m)	(m)	$3.90M	(m)
2025-06-30	Reported	-$14.68M*	-$14.78M	$94.00K*	$121.00K	-12134.71%*	(m)	-$8.33M*	(m)	(m)	$3.32M	(m)
2025-03-31	Reported	-$14.29M	(m)	(m)	(m)	-13109.17%	(m)	-$12.79M	(m)	(m)	$4.01M	(m)
2024-12-31	Reported	-$12.48M	(m)	(m)	(m)	-8262.25%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$12.50M*	-$12.60M	$101.00K*	$165.00K	-7575.76%*	$0.00*	-$10.46M*	(m)	(m)	$3.13M	(m)
2024-06-30	Reported	-$12.44M*	-$12.54M	$105.00K*	$163.00K	-7631.90%*	$0.00*	-$9.23M*	(m)	(m)	$3.21M	(m)
2024-03-31	Reported	-$10.83M	(m)	(m)	(m)	-5283.41%	$80.00K	-$7.74M	(m)	(m)	$3.13M	(m)
2023-12-31	Reported	-$10.23M	(m)	(m)	(m)	-6557.05%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$10.71M*	-$10.82M	$107.00K*	$141.00K	-7597.87%*	$315.00K*	-$7.96M*	(m)	(m)	$2.94M	(m)
2023-06-30	Reported	-$12.11M*	-$12.21M	$98.00K*	$108.00K	-11212.96%*	$251.00K*	-$7.13M*	(m)	(m)	$4.30M	(m)
2023-03-31	Reported	-$11.96M	(m)	(m)	(m)	-14412.05%	$8.00K	-$8.66M	(m)	(m)	$3.08M	(m)
2022-12-31	Reported	-$9.31M	(m)	(m)	(m)	-7270.31%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$8.91M*	-$8.99M	$81.00K*	$93.00K	-9582.80%*	$448.00K*	-$7.49M*	(m)	(m)	$3.08M	(m)
2022-06-30	Reported	-$10.40M*	-$10.44M	$38.00K*	$91.00K	-11434.07%*	$312.00K*	-$6.70M*	(m)	(m)	$3.09M	(m)
2022-03-31	Reported	-$11.04M	(m)	(m)	(m)	-14922.97%	$171.00K	-$10.25M	(m)	(m)	$3.94M	(m)
2021-12-31	Reported	-$9.41M	(m)	(m)	(m)	-7077.44%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$6.89M*	-$7.00M	$110.00K*	$86.00K	-8009.30%*	$98.00K*	-$5.46M*	(m)	(m)	$2.93M	(m)
2021-06-30	Reported	-$6.78M*	-$6.89M	$109.00K*	$68.00K	-9970.59%*	$0.00*	-$4.30M*	(m)	(m)	$2.84M	(m)
2021-03-31	Reported	-$5.32M	(m)	(m)	(m)	-7393.06%	$0.00	-$5.88M	(m)	(m)	$2.23M	(m)
2020-12-31	Reported	-$6.38M	(m)	(m)	(m)	-5361.34%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$4.25M*	-$4.36M	$115.00K*	$136.00K	-3123.53%*	$154.00K*	-$3.53M*	(m)	(m)	$1.64M	(m)
2020-06-30	Reported	-$3.99M*	-$4.10M	$115.00K*	$43.00K	-9272.09%*	$0.00*	-$4.29M*	(m)	(m)	$1.67M	(m)
2020-03-31	Reported	-$4.01M	(m)	(m)	(m)	-5889.71%	$0.00	-$3.37M	(m)	(m)	$1.49M	(m)
2019-12-31	Reported	-$4.17M	(m)	(m)	(m)	-4430.53%	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$4.08M*	-$4.21M	$123.87K*	$51.69K	-7900.64%*	$62.35K*	-$3.19M*	(m)	(m)	$1.44M	(m)
2019-06-30	Reported	-$4.10M*	-$4.22M	$122.18K*	$36.85K	-11119.56%*	$0.00*	-$3.44M*	(m)	(m)	$1.43M	(m)
2019-03-31	Reported	-$3.83M	(m)	(m)	(m)	-6183.36%	$5.27K	-$3.36M	(m)	(m)	$1.38M	(m)
2018-12-31	Reported	-$3.95M	(m)	(m)	(m)	-5057.71%	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$3.64M*	-$3.86M	$218.28K*	(m)	(m)	$0.00*	(m)	(m)	(m)	$1.67M	(m)
2018-06-30	Reported	-$4.21M*	-$4.44M	$231.01K*	(m)	(m)	$0.00*	(m)	(m)	(m)	$2.15M	(m)
2018-03-31	Reported	-$4.4M	(m)	(m)	(m)	-4396.56%	$5.10K	(m)	(m)	(m)	$2.50M	(m)
2017-12-31	Reported	-$3.49M	(m)	(m)	(m)	-1888.22%	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$5.49M*	-$5.80M	$311.03K*	(m)	(m)	$115.51K*	(m)	(m)	(m)	$4.08M	(m)
2017-06-30	Reported	-$5.57M*	-$5.89M	$314.99K*	(m)	(m)	$9.29K*	(m)	(m)	(m)	$4.67M	(m)
2017-03-31	Reported	-$9.79M	(m)	(m)	(m)	-10306.06%	$11.45K	(m)	(m)	(m)	$3.60M	(m)
2016-12-31	Reported	-$9.41M	(m)	(m)	(m)	-13817.97%	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	-$9.72M*	-$9.92M	$203.78K*	(m)	(m)	$126.91K*	(m)	(m)	(m)	(m)	(m)
2016-06-30	Reported	-$9.65M*	-$9.98M	$332.89K*	(m)	(m)	$318.84K*	(m)	(m)	(m)	(m)	(m)
2016-03-31	Reported	-$10.3M	(m)	(m)	(m)	-8550.23%	$352.02K	(m)	(m)	(m)	(m)	(m)
2015-12-31	Reported	-$7.26M	(m)	(m)	(m)	-9165.24%	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	-$6.31M*	-$6.41M	$97.62K*	(m)	(m)	$569.02K*	(m)	(m)	(m)	(m)	(m)
2015-06-30	Reported	-$6.55M*	-$6.63M	$84.46K*	(m)	(m)	$440.87K*	(m)	(m)	(m)	(m)	(m)
2015-03-31	Reported	-$4.78M	(m)	(m)	(m)	-3764.06%	$247.10K	(m)	(m)	(m)	(m)	(m)
2014-12-31	Reported	-$4.44M	(m)	(m)	(m)	-7869.93%	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	-$3.88M*	-$3.94M	$58.30K*	(m)	(m)	$101.97K*	(m)	(m)	(m)	(m)	(m)
2014-06-30	Reported	-$3.18M*	-$3.24M	$57.77K*	(m)	(m)	$15.15K*	(m)	(m)	(m)	(m)	(m)
2014-03-31	Reported	-$3.21M	(m)	(m)	(m)	-2889.61%	$118.51K	(m)	(m)	(m)	(m)	(m)
2013-12-31	Reported	-$2.8M	(m)	(m)	(m)	-5919.63%	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	-$3.04M*	-$3.08M	$41.60K*	(m)	(m)	$210.96K*	(m)	(m)	(m)	(m)	(m)
2013-06-30	Reported	-$2.35M*	-$2.37M	$26.15K*	(m)	(m)	$266.79K*	(m)	(m)	(m)	(m)	(m)
2013-03-31	Reported	-$2.37M	(m)	(m)	(m)	-1991.27%	$93.35K	(m)	(m)	(m)	(m)	(m)
2012-12-31	Reported	-$1.42M	(m)	(m)	(m)	-869.17%	(m)	(m)	(m)	(m)	(m)	(m)
2012-09-30	Reported	-$1.03M*	-$1.04M	$12.36K*	(m)	(m)	$71.25K*	(m)	(m)	(m)	(m)	(m)
2012-06-30	Reported	-$1.24M*	-$1.25M	$7.79K*	(m)	(m)	$42.96K*	(m)	(m)	(m)	(m)	(m)
2012-03-31	Reported	-$1.12M	(m)	(m)	(m)	-3291.15%	$98.01K	(m)	(m)	(m)	(m)	(m)
2011-12-31	Reported	-$874,643.00	(m)	(m)	(m)	-2591.53%	(m)	(m)	(m)	(m)	(m)	(m)
2011-09-30	Reported	-$729.58K*	-$732.15K	$2.58K*	(m)	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)
2011-06-30	Reported	-$644.87K*	-$647.45K	$2.58K*	(m)	(m)	$1.00*	(m)	(m)	(m)	(m)	(m)
2011-03-31	Reported	-$717,423.00	(m)	(m)	(m)	-805.35%	$1.53K	(m)	(m)	(m)	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$48.6M	(m)	(m)	(m)	-8194.94%	$44.00K	-$37.92M	(m)	(m)	$14.22M	$0.00
2024-12-31	Reported	-$48.25M	(m)	(m)	(m)	-7063.98%	$80.00K	-$37.69M	(m)	(m)	$12.48M	$0.00
2023-12-31	Reported	-$45.01M	(m)	(m)	(m)	-9224.18%	$582.00K	-$30.89M	(m)	(m)	$13.04M	$0.00
2022-12-31	Reported	-$39.67M	(m)	(m)	(m)	-10276.17%	$1.01M	-$33.82M	(m)	$27.10M	$13.18M	$0.00
2021-12-31	Reported	-$28.4M	(m)	(m)	(m)	-7911.98%	$205.00K	-$23.04M	(m)	$17.40M	$11.84M	$0.00
2020-12-31	Reported	-$18.62M	(m)	(m)	(m)	-5087.43%	$211.00K	-$16.32M	(m)	$11.24M	$8.22M	$0.00
2019-12-31	Reported	-$16.18M	(m)	(m)	(m)	-6615.76%	$67.62K	-$13.27M	(m)	(m)	$5.76M	$0.00
2018-12-31	Reported	-$16.19M	(m)	(m)	(m)	-4280.43%	$5.10K	-$13.20M	(m)	(m)	$8.01M	$0.00
2017-12-31	Reported	-$24.35M	(m)	(m)	(m)	-4817.58%	$101.10K	(m)	(m)	(m)	$14.23M	$0.00
2016-12-31	Reported	-$39.08M	(m)	(m)	(m)	-10254.25%	$823.48K	(m)	(m)	(m)	(m)	$0.00
2015-12-31	Reported	-$24.89M	(m)	(m)	(m)	-7958.44%	$2.24M	(m)	(m)	(m)	(m)	$0.00
2014-12-31	Reported	-$14.71M	(m)	(m)	(m)	-5250.36%	$363.29K	(m)	(m)	(m)	(m)	$0.00
2013-12-31	Reported	-$10.56M	(m)	(m)	(m)	-4073.36%	$649.78K	(m)	(m)	(m)	$7.00M	$0.00
2012-12-31	Reported	-$4.81M	(m)	(m)	(m)	-1067.33%	$274.08K	(m)	(m)	(m)	$3.38M	(m)
2011-12-31	Reported	-$2.97M	(m)	(m)	(m)	-1151.17%	$1.53K	(m)	(m)	(m)	$2.32M	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Black Diamond Therapeutics, Inc. (BDTX)	United States	$0.109B	-2.48
COGNITION THERAPEUTICS INC (CGTX)	United States	$0.090B	-6.52
Pelthos Therapeutics Inc. (PTHS)	United States	$0.086B	-1.20
Atara Biotherapeutics, Inc. (ATRA)	United States	$0.086B	-6.48
LENZ Therapeutics, Inc. (LENZ)	United States	$0.117B	-1.41
Vaxart, Inc. (VXRT)	United States	$0.080B	3.84
enGene Therapeutics Inc. (ENGN)		$0.129B	-0.92
Kalaris Therapeutics, Inc. (KLRS)	United States	$0.073B	-2.19
Neumora Therapeutics, Inc. (NMRA)	United States	$0.132B	-1.48
Armata Pharmaceuticals, Inc. (ARMP)	United States	$0.132B